Objective. To study the effect of the 8-week treatment with atorvastatin on the quality of life (QOL) of hypertensive patients with metabolic syndrome. Design and methods. An 8-week open prospective study included 35 patients with essential hypertension (stage II), associated with metabolic syndrome. Along with the complete clinical, laboratory and instrumental examination, taken in a specialized cardiology clinic, MOS SF-36® questionnaire was used to study the QOL during atorvastatin treatment. Results and conclusions. The 8-week atorvastatin treatment (20 to 40 mg/day titrated individually) both contributes to statistically signifi cant reduction of atherogenic fractions of cholesterol and provides a positive dynamics of subjective evaluation of QOL by SF-36® scales in hypertensive patients with metabolic syndrome.

Aim of study: to examine the features of expression of CD-markers of blood mononuclear leukocytes and their functional activity in the metabolic syndrome. Conducted a cross-sectional (transverse) study of 76 patients with essential hypertension (EH) II stage (BP <180/110 mm Hg.) [10] in conjunction with the metabolic syndrome and 20 people, formed the control group. Along with a complete clinical, laboratory and instrumental examination taken in a specialized cardiological clinic was conducted determination of surface markers of lymphocytes CD4+, CD8+ and monocytes CD36+ and assessment of the level of spontaneous production of reactive oxygen blood mononuclear leukocytes. Found that in patients with the metabolic syndrome compared with the control group the proportion of CD4+ lymphocytes and the level of spontaneous ROS production by mononuclear leukocytes significantly higher. The positive correlated interconnection between these indicators and the number of CD36+ monocytes with the majority of clinical and metabolic markers of MS confirmes their participation in mechanism of immune inflammation and oxidative stress in this pathological process.

AIM:To study pleiotropic effects of atorvastatin during 8-week therapy of metabolic syndrome and estimate their relationship with dynamics of quality of life characteristics (QLC).MATERIAL AND METHODS:This 8-week study included 36 patients with stage II hypertensive disease associated with metabolic syndrome (MS). Comprehensive clinical, laboratory and instrumental examination was supplemented by QLC assessment using the MOS SF-36 questionnaire.RESULTS:8-week therapy of stage II hypertensive disease associated with metabolic syndrome using individually selected doses of atorvastatin (20 to 40 mg/d) significantly reduced atherogenic cholesterol fraction and serum leptin levels; it had positive effect on carbohydrate and purine metabolism and safely maintained positive dynamics of subjective assessment of most points of the MOS SF-36 questionnaire.

Objective. To assess the quality of life (QOL) in hypertensive patients and to study the interrelation between the QOL indicators and the metabolic syndrome (MS) components. Design and methods. We examined 46 patients with stage II hypertension and 18 healthy subjects. Standard full clinical, laboratory and instrumental examination as well as QOL by MOS SF-36® questionnaire were performed in all subjects. Results and conclusions. Hypertensive patients and healthy subjects differed by the scale of general health (GH), physical functioning (PF), pain intensity (BP) and vitality (VT). We detected reverse correlation between the QOL indicators and all the components of MS, such as abdominal obesity, hyperglycemia, dislipoproteinemia, degree of arterial hypertension, as well as with fibrinogen level.

A retrospective cohort study was carried out to elucidate the safety of statin administration in patients suffering from polymorbidity with high coronary risk and severe diseases associated with metabolic syndrome. The study included 89 patients aged 39-80 years who regularly took statins in individually selected doses for the period of 1-3 years and underwent routine laboratory monitoring of efficiency and safety of the therapy at the out-patient central regional hospital. A longterm statin therapy, even in small doses, contributed to statistically significant reduction in the total cholesterol level and was safe for polymorbid patients with high coronary risk. This was proven by the lack of significant increase in the number of biochemical indicators including level of transaminases, bilirubin, urea, uric acid, and creatinine during the treatment. Patients who regularly took atorvastatin achieved the target level of total cholesterol 1.5 times more often with shorter duration of treatment than those who took other statins.

Study objective: study of the interrelation between the indicators of quality of life (QL) in patients with coronary heart disease and risk factors of this pathology united by the framework of metabolic syndrome (MS) and the degree of activity of systemic inflammatory response. 110 patients with coronary heart disease have been examined. Along with the complete clinical, laboratory and instrumental examination, adopted in a specialized cardiology clinic, the study of QL was carried out with the help of the MOS SF-36 questionnaire, and also the analysis of activity of systemic inflammatory response was performed. It was shown that in the cluster of MS components there is a reverse correlation interrelation with abdominal obesity, hypertension and hyperglycemia. Also, a reverse correlation interrelation between the indicators of QL and some non-specific inflammatory markers (erythrocyte sedimentation rate, the concentration of C-reactive protein in blood) was discovered.